Literature DB >> 9802920

Mutations in T cell receptor zeta chain mRNA of peripheral T cells from systemic lupus erythematosus patients.

K Tsuzaka1, T Takeuchi, N Onoda, M Pang, T Abe.   

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown aetiology. Although it has been reported that T cells might be responsible for the pathogenesis of SLE, it remains unclear whether immune aberrations of SLE T cells are the primary event in this pathological process. We have recently reported that tyrosine phosphorylation and expression of the T cell receptor zeta chain (TCR zeta) was significantly decreased in SLE T cells and that two SLE patients exhibited a 36 bp, exon 7 deletion of the TCR zeta mRNA. To investigate further common mutations in TCR zeta mRNA among SLE patients, mRNA was isolated from the peripheral blood T cells of two normal controls, two systemic sclerosis (SSc) patients, and eight SLE patients. TCR zeta cDNA was amplified by RT-PCR. Five out of the eight SLE patients exhibited abnormal migration patterns of the TCR zeta cDNA in PCR single stranded conformational polymorphism analysis. PCR products were ligated into pUC18 and five clones obtained were sequenced. Analysis of the nucleotide sequences revealed that all of the five pUC18 clones from the normal controls and SSc patients had the normal nucleotide sequence, whereas all eight SLE patients had mutations in TCR zeta cDNA accompanied by predicted amino acid substitutions. Mutations found in six of these patients corresponded to those of the third immunoreceptor tyrosine-based activation motif (ITAM) domain or the GTP/GDP binding site in TCR zetaThus, these mutations in TCR zeta mRNA could be responsible for the decreased expression of the TCR zeta protein in SLE T cells. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802920     DOI: 10.1006/jaut.1998.0223

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

Review 1.  Genetics and systemic lupus erythematosus.

Authors:  B P Tsao; J M Grossman
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Cutting Edge: CD3 ITAM Diversity Is Required for Optimal TCR Signaling and Thymocyte Development.

Authors:  Matthew L Bettini; Po-Chein Chou; Clifford S Guy; Thomas Lee; Kate M Vignali; Dario A A Vignali
Journal:  J Immunol       Date:  2017-07-21       Impact factor: 5.422

Review 3.  TCRzeta mRNA splice variant forms observed in the peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  Kensei Tsuzaka; Kyoko Nozaki; Chika Kumazawa; Kiyono Shiraishi; Yumiko Setoyama; Keiko Yoshimoto; Tohru Abe; Tsutomus Takeuchi
Journal:  Springer Semin Immunopathol       Date:  2006-09-05

Review 4.  An update on genetic studies of systemic lupus erythematosus.

Authors:  Betty P Tsao
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

5.  Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus.

Authors:  Keiko Yoshimoto; Yumiko Setoyama; Kensei Tsuzaka; Tohru Abe; Tsutomu Takeuchi
Journal:  J Biomed Biotechnol       Date:  2010-09-06

6.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha.

Authors:  Joanna M Clark; Alexander E Annenkov; Manvinder Panesar; Pia Isomäki; Yuti Chernajovsky; Andrew P Cope
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

Review 8.  Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease.

Authors:  Pingping Ren; Luying Lu; Shasha Cai; Jianghua Chen; Weiqiang Lin; Fei Han
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.